VEGFA and neoplasm: The immune modulatory effects of antiangiogenic agents targeting the VEGF/VEGF receptor on various immune cells, including effector T cells, Tregs, myeloid‐derived suppressor cells, dendritic cells, tumor‐associated macrophages (TAMs), and mast cells, in the tumor microenvironment of NSCLC, have been well‐documented.36